Sun Pharma Gets US Health Regulator Nod To Market Generic Medication

Friday February 10, 2023.

Sun Pharmaceutical Industries on Friday said its subsidiary has received approval from the US health regulator to market a generic medication used in the treatment of multiple myeloma.

Topics

Sun Pharma | USFDA | Medicines

Press Trust of India | New Delhi

Last Updated at February 10, 2023 22:30 IST

Sun Pharmaceutical Industries on Friday said its subsidiary has received approval from the US health regulator to market a generic medication used in the treatment of multiple myeloma.

The company has received final approval from the US Food and Drug Administration (USFDA) for the generic lenalidomide capsules in multiple strengths, Sun Pharma said in a statement.

In June 2021, Sun Pharma entered into a settlement with Celgene Corporation (Celgene) to resolve the patent litigation regarding its generic lenalidomide capsules.

Under the terms of this settlement, Celgene granted Sun Pharma a license to patents required to manufacture and sell certain limited quantities of generic lenalidomide capsules in the US, beginning sometime after March 2022.

In addition, the license allows Sun Pharma to manufacture and sell an unlimited quantity of generic lenalidomide capsules in the US beginning January 31, 2026.

Shares of Sun Pharma were trading 0.48 per cent down at Rs 1,002 apiece on the BSE.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

First Published: Fri, February 10 2023. 15:08 IST

';$('#story-newsss .item a').each(function(i){var atext=$(this).text();var aurl=$(this).attr('href');gethtml+='';});gethtml+='

';$("#story-news").html(gethtml);setTimeout(function(){$(".story-slider").slick({dots:false,infinite:true,prevArrow:".slick-prev",nextArrow:".slick-next",arrows:true,slidesToShow:2,slidesToScroll:2,})},500);}}});$.ajax({url:'/request-handler/get-latest-articles/catId/101/cache-control/1800',async:true,success:function(data){$("#next-prev").html(data);var owl=$("#next-prev");if(data!=''){var checkIdExists=$(".more-stories-pagination.disNone div").hasClass("latestArticleId-123021000655");if(checkIdExists){$(".latestArticleId-123021000655").remove();}else{$(".latestArticleLastId").remove();}$(".more-stories-pagination.disNone").show();}if(owl.owlCarousel){owl.owlCarousel({items:2,itemsDesktop:[980,2],itemsDesktopSmall:[900,2],itemsTablet:[360,2],itemsMobile:false});}$(".next").click(function(){owl.trigger('owl.next');});$(".prev").click(function(){owl.trigger('owl.prev');});$(".play").click(function(){owl.trigger('owl.play',1000);});$(".stop").click(function(){owl.trigger('owl.stop');});}});function unFollowColumnist(){var author_id='0';var userInfo=decodeURIComponent(getCookie('_userLoggedIn'));var isPaidUser="N";if(userInfo!=null&&userInfo!='undefined'){var userType=JSON.parse(userInfo);if(userType!=null&&userType!='undefined'&&userType.s!='undefined'&&userType.s=='t'){isPaidUser="Y";}else{isPaidUser="N";}}if(author_id!=''){if(confirm("Are you sure to unfollow this columnist!")==true){$.ajax({url:'/request-handler/article/unmap-user-columnist',type:'post',data:{'authorId':author_id,'isPaidUser':isPaidUser},success:function(msg){if(msg=='success'){location.reload();return false();}else{message='Please try again';alert(message);return false();}}});}}else{alert("Invalid columnist request!");return false();}}function followColumnist(){var author_id='0';var userInfo=decodeURIComponent(getCookie('_userLoggedIn'));var isPaidUser="N";var isLoggedIn="N";if(userInfo!=null&&userInfo!='undefined'){var userType=JSON.parse(userInfo);if(userType!=null&&userType!='undefined'&&userType.s!='undefined'&&userType.s=='t'){isPaidUser="Y";isLoggedIn="Y";}else if(userType!=null&&userType!='undefined'){isPaidUser="N";isLoggedIn="Y";}}if(isLoggedIn=="Y"){if(author_id!=''){$.ajax({url:'/request-handler/article/map-user-columnist',type:'post',data:{'authorId':author_id,'isPaidUser':isPaidUser},success:function(msg){if(msg=='success'){location.reload();return false();}else{customLogin();}}});}else{alert("Invalid columnist request!");return false();}}else if(isLoggedIn=="N"){customLogin();}}function unLockArticle(){var article_id='123021000655';var userInfo=decodeURIComponent(getCookie('_userLoggedIn'));var isPaidUser="N";if(userInfo!=null&&userInfo!='undefined'){var userType=JSON.parse(userInfo);if(userType!=null&&userType!='undefined'&&userType.s!='undefined'&&userType.s=='t'){isPaidUser="Y";}else{isPaidUser="N";}}if(article_id!=''){$.ajax({url:'/request-handler/article/unlock-article',type:'post',data:{'article_id':article_id,'isPaidUser':isPaidUser},success:function(msg){console.log(msg);if(msg=='success'){location.reload();return false();}else{$(".iframe").trigger('click');}}});}else{alert("Invalid columnist request!");return false();}}function customLogin(){var author_id='0';var articleId='123021000655';var parentUrl=window.location.href;if(parentUrl.indexOf("?")>-1){parentUrl=parentUrl.substr(0,parentUrl.indexOf("?"));}$("#sign_in").fancybox({maxWidth:600,maxHeight:580,fitToView:false,autoSize:false,closeClick:false,href:'/core/request-handler/sign-in-content?ref='+parentUrl+'&fc='+author_id+'&articleId='+articleId,openEffect:'none',closeEffect:'none'});$('.fancybox').fancybox();$("#sign_in").trigger('click');}function showhide(){var div=document.getElementById("follow");if(div.style.display!=="block"){div.style.display="block";}else{div.style.display="none";}}$(document).ready(function(){$('.articleCompanyStockInfo').hide();$('.bsNewArticleCompanyStockInfo').show();var userInfo=decodeURIComponent(getCookie('_userLoggedIn'));if(userInfo!=null&&userInfo!='undefined'){var userType=JSON.parse(userInfo);if(userType!=null&&userType!='undefined'&&userType.s!='undefined'&&userType.s=='t'){$(".article-middle-banner").css("display","none");}else{$(".article-middle-banner").css("display","block");}}else{$(".article-middle-banner").css("display","block");}});

Sun Pharma Gets US Health Regulator Nod To Market Generic Medication

Sun Pharmaceutical Industries on Friday said its subsidiary has received approval from the US health regulator to market a generic medication used in the treatment of multiple myeloma.

Subscribe to Business Standard Premium

The Battle For Depositors: US Lenders Ramp Up Efforts Amidst Rate Uncertainty

Beyond Capital: Unveiling The Complexities Of Bank Failure Prediction

Central Banks And The Economic Horizon: Steering Through Uncertaintie

Transforming Financial Operations With Robotic Process Automation

The Role Of Machine Learning In Fraud Detection

Principles Of Islamic Banking And Finance

navigation

media coverage

follow us